reason report
year nextseq replac cycl expand low-
bottom line remain outperform view
major popul develop emerg
world like sequenc one genet test
lifetim creat massiv market benefit
revenu came pre-announce revenue
number though chang full year guid
 y/i growth revenu larg back half load due key
nextseq launch time dtc key culprit firmli
believ year nextseq adopt launch
instrument latter part set trajectori growth throughout
year remain outperform pt
full year guid remain intact revenu cadenc back half
load guid impli essenti
flat y/i sequenti step-down larg driven expect
deliv novaseq vs near paus
research nextseq purchas nextseq launch
latter part custom wait purchas new product
continu declin dtc direct consum test given end-
market pressur ultim believ stori lever
nextseq instrument ramp extend product
replac cycl even broadli
year nextseq remain confid
year nextseq extend new product replac
cycl larg number low mid-throughput lab find
challeng upgrad novaseq nextseq capac
nextseq believ proport increas
util provid upsid revenue growth
call link topic came away view recent launch
uptak bound occur nt among low-throughput research
set includ smaller academ core small biotech lab
look upgrad low-throughput miseq miseq upgrad
seek replac nextseq nextseq expand
lt outlook remain lever popul sequenc pop-seq
see pop-seq project begin scale contribut
meaning organ growth expect genom
sequenc uk biobank link genom us-bas
us gel/uk believ eventu scale
genom new revenue/ep estim move
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target believ
major popul develop emerg world like touch one
genet test lifetim creat massiv market believ stand
benefit market compani see sequenc market
number sampl depth coverag expand dramat next year
novaseq upcom instrument drive signific reduct sequenc cost
earlier hiseq current novaseq flow cell
like futur set path genom price beyond
high throughput platform also continu drive double-digit growth desktop system
includ nextseq essenti key high growth market includ non-invas
pre-nat test nipt faster turn-around sampl oncolog continu
domin sequenc market world-wide life scienc genet test reproduct health
oncolog market share revenu market share sequenc unit
believ ilmn market share accuraci throughput enterpris level servic product
factor continu keep custom bound despit custom
consid higher price still direct strong competit sight somewhat
unbound market believ continu domin next-gen sequenc keep
drive sequenc cost lower lead elast demand sampl deeper
share current trade price-to-earnings consensu ep
multipl view potenti unbound market opportun
major popul develop develop world like touch
sequenc form test next year use dcf analysi beta
long-term growth rate wacc arriv price target
believ remain strong forc sequenc market see revenu growth
continu outer year addit believ long-term growth rate
conserv estim given sequenc repres somewhat unbound market
opportun view still applic continu explor beyond
current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given near-monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
bp increas
revenue q/q
seq consum
roughli line
higher
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report svb leerink estim
 depreci alreadi ex amort
